
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is positioned for continued growth and success, with a strong pipeline and an established track record of commercial success. With leading drugs in multiple indications, including a partnership with Novartis, and a new dermatology product approved for two conditions in 2021 and 2022, Incyte's potential for revenue generation is significant. The company has also seen strong uptake in new patients and high demand for its drugs, and has a clear strategy for continued growth and expansion in the coming years. With a projected revenue of $4.7-$4.9 billion in 2026 and a potential peak sales estimate of $1 billion for its oral option for HS, Incyte represents a solid investment opportunity in the biotech sector.
Bears say
Incyte is a biopharmaceutical company with a successful lead product, Jakafi, and a diverse product pipeline focused on rare blood cancers, graft versus host disease, and dermatology. Despite acknowledging some side effects at a higher dose, Incyte believes that having flexibility in dosing could help with market positioning and attracting physicians. While concerns may arise from Opzelura's lighter-than-expected guidance, Incyte's long-term goal of doubling the size of its business appears achievable through current indication-specific growth and international expansion efforts. Additionally, the company's late-stage oncology portfolio is undervalued, with upcoming data disclosures for several key assets in 2026. However, the near-term catalyst calendar is light, and exclusions of certain products like '734 and Jakafi XR in the financial analysis may impact future revenue and growth.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares